Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Aurion Biotechnologies | 2022 | Series Unknown | $120.0M | Seattle |
| Oncorus | 2022 | Post Ipo Debt | $20.0M | Cambridge |
| Stellar Health | 2022 | Series Unknown | Undisclosed | New York |
| Jaguar Gene Therapy | 2022 | Series Unknown | Undisclosed | Lake Forest |
| Vibliome | 2022 | Series A | $38.0M | Bozeman |
| ConcertoCare | 2022 | Series B | $105.0M | Woburn |
| Appello Pharmaceuticals | 2022 | Series B | $13.5M | Nashville |
| CareMax | 2022 | Post Ipo Equity | $1.0M | Miami |
| DeepSight Technology | 2021 | Series A | $25.0M | San Francisco |
| Novocardia | 2021 | Series A | $53.7M | New York |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 126 | Aurion Biotechnologies | Series Unknown | $120.0M | Seattle, United States |
| 127 | Oncorus | Post Ipo Debt | $20.0M | Cambridge, United States |
| 128 | Stellar Health | Series Unknown | Undisclosed | New York, United States |
| 129 | Jaguar Gene Therapy | Series Unknown | Undisclosed | Lake Forest, United States |
| 130 | Vibliome | Series A | $38.0M | Bozeman, United States |
| 131 | ConcertoCare | Series B | $105.0M | Woburn, United States |
| 132 | Appello Pharmaceuticals | Series B | $13.5M | Nashville, United States |
| 133 | CareMax | Post Ipo Equity | $1.0M | Miami, United States |
| 134 | DeepSight Technology | Series A | $25.0M | San Francisco, United States |
| 135 | Novocardia | Series A | $53.7M | New York, United States |
Aurion Biotechnologies is a clinical-stage biotech company.
Oncorus is an immuno-oncology company developing oncolytic viruses to fight cancer.
Stellar Health empowers providers and practice staff to deliver high-quality care through real-time notifications and meaningful incentives.
Jaguar Gene Therapy is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases.
Vibliome is developing a new family of therapeutics for the treatment of cancer, contraception and other indications.
ConcertoCare is a provider of at-home and comprehensive care for seniors and other adults.
Appello Pharmaceuticals is a preclinical-stage company focused on CNS disorders.
CareMax is a technology-enabled care platform providing value-based care and chronic disease management to seniors.
DeepSight Technology's vision is to reinvent diagnostic imaging.
Novocardia treats cardiovascular care.
Singular Genomics is a biotech company focused on delivering genomic technologies for the advancement of science and medicine.
Cureatr is a medication management and optimization company that sells tech and tech-enabled services to at-risk health care enterprises.
ARTMS is a developer of technology that transforms the production of diagnostic imaging isotopes.
Neomorph is a biotechnology company.
Cystetic Medicines develops a treatment that potentially could help people with cystic fibrosis (CF), regardless of genetic mutation.
Bridge Medicines is a drug discovery company
Springtide Child Development is a modern clinic to support children with developmental delays.
Great Lakes Discoveries is a company set up by University of Michigan to boost drug commercialisation efforts.
Farapulse commercializing an innovative collection of catheter-based tools used to treat atrial fibrillation.
Four Points Innovation is a private company aiming to accelerate drug discovery and development.
Contessa operates Home Recovery Care, combining all the essential elements of inpatient hospital care in the comfort of patients’ homes.
GrayBug is a biopharmaceutical company that develops transformative medicines for ocular diseases.
Chondrial Therapeutics is clinical-stage biotechnology that focuses on developing orphan drugs for mitochondrial diseases.
TriNetX is a health research network that connects drug discovery and development from pharmaceutical companies.
Stelexis Therapeutics is a company utilizes pre-cancerous stem cells to discover and develop transformative therapies.
Deerfield has invested in 161 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Deerfield's top investment sectors include Health Care, Biotechnology, Medical, Pharmaceutical, Therapeutics. The firm invests across 25 different industry categories.
Among tracked funding rounds, Singular Genomics received $130.5M in a Convertible Note round. Deerfield's total known invested capital is $8.0B.
Deerfield's average investment size is $78.0M across its portfolio of 161 companies.
Recent Deerfield portfolio additions include Aurion Biotechnologies, Oncorus, Stellar Health, Jaguar Gene Therapy, Vibliome. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors